Cyclin-dependent kinase inhibitor 1C (UniProt: P49918; also known as Cyclin-dependent kinase inhibitor p57, p57Kip2) is encoded by the CDKN1C (also known as KIP2) gene (Gene ID: 1028) in human. p57Kip2, is a member of the Cip/Kip family of cyclin-dependent kinase (CDK) inhibitors. It is characterized by an N-terminal domain that is crucial for its inhibitory activity towards CDKs, particularly CDK2 and CDK4. p57Kip2/CDKN1C functions as a potent inhibitor of cell cycle progression. By binding to and inhibiting CDKs, it plays a critical role in regulating the G1 phase of the cell cycle. p57Kip2 also participates in other cellular processes, including apoptosis and senescence. CDKN1C is expressed in a variety of tissues. Its expression is tightly regulated by genetic and epigenetic mechanisms, including imprinting, where typically only the maternal allele is expressed. The expression of CDKN1C can be influenced by developmental cues and stress signals. Mutations or dysregulation of CDKN1C are associated with developmental disorders such as Beckwith-Wiedemann syndrome, a condition characterized by overgrowth and an increased risk of childhood tumors. Additionally, alterations in CDKN1C expression or function can contribute to cancer development, as its role in inhibiting cell cycle progression is critical for preventing uncontrolled cell division. Loss of CDKN1C function can lead to unchecked cell proliferation, a hallmark of cancer. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1H11 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects p57Kip2. It targets an epitope within 25 amino acids from the N-terminal half.

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal half of human p57Kip2.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected p57Kip2 protein in HeLa cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected p57Kip2 in lysates from dexamethasone (100 nM), treated A549 cells, mouse kidney tissue, rat adrenal tissue, and human kidney tissue; and a 1:10,000 dilution from Jurkat cell lysate.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected p57Kip2 in human placenta tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected p57Kip2 in Jurkat cells and MCF7 cells.

Affinity Binding Assay: A representative lot of this antibody bound with p57Kip2 peptide with at least one hundred thousand-fold (100,000X) higher affinity than with non-specific control peptide.

Flow Cytometry Analysis: 1 µg from a representative lot detected p57Kip2 in one million MCF7 cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.